Marketplace As Enforcer? FDA Cedes Onus To Litigants – Attorney
This article was originally published in The Rose Sheet
Executive Summary
Pointing to the uptick in consumer class actions targeting cosmetics claims and the lull in FDA enforcement action in the sector since the 2012 warning-letter blitz, Arent Fox partner Georgia Ravitz speculates that the agency is “letting the marketplace now scrutinize product label claims to determine whether they’re false or misleading.”